Navigation Links
AMIHOT II trial data presented at TCT
Date:10/23/2007

Late-breaking data presented at TCT 2007, the scientific symposium of the Cardiovascular Research Foundation (CRF), show that an infusion of blood that is supersaturated with oxygen (SSO2) can reduce the amount of damaged heart muscle following a heart attack.

Despite successful reperfusion or restoration of blood flow to the heart with angioplasty following a heart attack there is often an area of infarction, or damaged heart muscle caused by the death of cells due to the interruption of oxygen carrying blood.

In the AMIHOT II trial, investigators led by Gregg W. Stone, MD, Chairman, Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center sought to determine the efficacy and safety of infusing SSO2 into the previously blocked artery after an angioplasty procedure.

Among high-risk patients with acute anterior myocardial infarction (heart attack) undergoing successful angioplasty within 6 hours of symptom onset, infusion of SSO2 into the myocardial infarct territory results in a significant reduction in the size of the 'infarct zone, the amount of damaged heart tissue, Stone said.

The AMIHOT II trial was conducted with 304 patients randomized at 20 sites in four countries.

Data from the study show that the size of the infarct zone was 6.5 percent lower in the patients treated with SSO2 than in control patients who did not receive the therapy.

In addition, at 30 days after the treatment, the rates of Major Adverse Cardiac Events (MACE) were statistically equivalent between the two groups.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
917-558-5180
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1

Related medicine news :

1. Man against HIV – new vaccine ready for human trials
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Male contraceptive in trial
4. How do patients benefit of clinical trials
5. Glenmark’s new molecule to go through trial
6. Clinical trials need to be more frank
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Hormone Replacement Therapy increases the risk of endometrial cancer
9. Atrial fibrillation predicts for acute ischaemic stroke
10. Spray on contraceptive clears Phase I trial
11. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that Frost & ... Innovation Award for Its fibromyalgia pain management device. The ... market research by Frost & Sullivan,s industry experts. ... product, the AVACEN 100, offers a safe and effective solution ... ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
Breaking Medicine Technology: